TransThera Biosciences

LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States

Retrieved on: 
星期一, 二月 22, 2021
Cardiology, Biotechnology, Diabetes, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Medical specialties, Companies, Economy of South Korea, AOC3, LG Chem, Non-alcoholic fatty liver disease, Steatohepatitis, LG Corporation, Potency, Hepatitis, LG Chem Life Sciences, TransThera Biosciences

LG Chem Life Sciences (LG Chem) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.

Key Points: 
  • LG Chem Life Sciences (LG Chem) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
  • LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (TransThera), a clinical-stage biotechnology company based in Nanjing, China.
  • LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH).
  • LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally.

LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor

Retrieved on: 
星期二, 十二月 1, 2020
Research, FDA, Clinical trials, Biotechnology, Managed care, Health, Pharmaceutical, Science, Oncology, Companies, Economy of South Korea, LG Chem, LG Corporation, TT-01025, NASH, LG Chem Life Sciences, TransThera Biosciences

LG Chem Life Sciences (LG Chem), a division of LG Chem, and TransThera Biosciences Co. Ltd. (TransThera), a clinical-stage biotechnology company based in Nanjing, China, announced today that U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TT-01025, a novel SSAO/VAP-1 inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) and other inflammatory diseases.

Key Points: 
  • LG Chem Life Sciences (LG Chem), a division of LG Chem, and TransThera Biosciences Co. Ltd. (TransThera), a clinical-stage biotechnology company based in Nanjing, China, announced today that U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TT-01025, a novel SSAO/VAP-1 inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) and other inflammatory diseases.
  • We acknowledge the LG Chem and TransThera teams for their commitment, seamless collaboration and strong team spirit during the IND preparation, commented Dr. Jennifer Sheng, Vice President of Biology at TransThera.
  • LG Chem reached an exclusive license agreement with TransThera Biosciences on August 17th, 2020 to research, develop, manufacture and commercialize TT-01025 in global region except Greater China and Japan.
  • LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally.